SCHEMBL2780100

SCHEMBL2780100

CNC(=O)OC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210398 0.77
SCHEMBL8771999 0.74
SCHEMBL6017119 0.73
SCHEMBL30722022 0.72
Bromide SCHEMBL16762436 0.72
SCHEMBL27532709 0.71
SCHEMBL9148785 0.71
SCHEMBL3589907 0.70
SCHEMBL514392 0.70
SCHEMBL29173796 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117580831-A GRK2 inhibitors and uses thereof 索纳塔治疗公司 2024-02-20 CN disclosed
CN-116669727-A Triazole-pyridinyl substituted azacyclohexylacetic acid compounds as LPA receptor antagonists 唯久生物有限公司 2023-08-29 CN disclosed
EP-3313816-B1 METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE OMEICOS THERAPEUTICS GMBH (DE) 2023-05-24 EP disclosed
CN-114751920-A Antitumor compounds 法马马有限公司 2022-07-15 CN disclosed
US-20210353569-A1 Analogs of CYP-Eicosanoids for Use in Treating or Preventing a Disorder Associated with Neovascularization and/or Inflammation OMEICOS THERAPEUTICS GMBH (DE) 2021-11-18 US disclosed
CN-108349880-B CYP eicosanoid metabolism robust analogs for treatment of cardiac disorders 奥迈科斯治疗公司 2021-03-09 CN disclosed
US-20190133976-A1 METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE OMEICOS THERAPEUTICS GMBH (DE) 2019-05-09 US disclosed
US-20190117597-A1 ANALOGS OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION MAX DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2019-04-25 US disclosed
EP-3435993-A1 ANALOGS OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION OMEICOS Therapeutics GmbH (DE) 2019-02-06 EP disclosed
CN-108349880-A The steady analog of CYP eicosanoid metabolics for treating heart disease 奥迈科斯治疗公司 2018-07-31 CN disclosed
US-20100152465-A1 Functionalized Ionic Liquids, and Methods of Use Thereof UNIVERSITY OF SOUTH ALABAMA (US) 2010-06-17 US disclosed
US-20080112866-A1 Functionalized ionic liquids, and methods of use thereof UNIVERSITY OF SOUTH ALABAMA (US) 2008-05-15 US disclosed
EP-1556390-A4 FUNCTIONALIZED IONIC LIQUIDS, AND METHODS OF USE THEREOF UNIV SOUTH ALABAMA (US) 2007-12-26 EP disclosed
US-7208605-B2 Functionalized ionic liquids, and methods of use thereof UNIVERSITY OF SOUTH ALABAMA (US) 2007-04-24 US disclosed
EP-1556390-A2 FUNCTIONALIZED IONIC LIQUIDS, AND METHODS OF USE THEREOF University Of South Alabama (US) 2005-07-27 EP disclosed
US-20040035293-A1 Functionalized ionic liquids, and methods of use thereof UNIVERSITY OF SOUTH ALABAMA 2004-02-26 US disclosed
WO-2003086605-A2 FUNCTIONALIZED IONIC LIQUIDS, AND METHODS OF USE THEREOF UNIVERSITY OF SOUTH ALABAMA (US) 2003-10-23 WO disclosed
US-5455249-A Antirejection agent, immunosuppressant, fungicide, antitumor agent WYETH 1995-10-03 US disclosed
US-5391730-A An immunsuppressantes, antiinflammatory agents, fungicides, antitumor agents AMERICAN HOME PRODUCTS CORPORATION (US) 1995-02-21 US disclosed
US-4059615-A INSECTICIDE, POLYMER INTERMEDIATE HOOKER CHEMICALS & PLASTICS CORPORATION (US) 1977-11-22 US disclosed